OncoMatch

OncoMatch/Clinical Trials/NCT05526079

Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

Is NCT05526079 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for rectal cancer.

Phase 2RecruitingHenry Ford Health SystemNCT05526079Data as of Jun 2026

The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Disease stage

Required: Stage T3/N0-N1M0, LOW T2

Clinical stage T3/N0-N1M0. Patients with low T2 who will need abdominal perineal resection are also eligible.

Demographics

Ages ≤ 95

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Ascension St. John Hospital · Detroit, Michigan

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05526079 currently recruiting?

Yes, this trial is currently recruiting patients.

What disease stage is eligible?

Stage T3/N0-N1M0 or LOW T2 is required.

Is there an age limit?

Yes. Patients must be 95 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify